June 4, 2017 effective as a standard 6-month course—with a difference in disease-free survival (DFS) of less than 1%—while reducing the risk of neurotoxicity and other adverse events. A subgroup analysis further showed that the 3-month course was most appropriate for low-risk patients (Abstract LBA1). In view of these findings, investigators in the IDEA...
Pro zobrazení tohoto obsahu je třeba být přihlášen.